Abstract
Despite significant advances in medical treatment, cardiovascular disease is still a major cause of morbidity and mortality in advanced countries. To improve the outcome, the further promotion of basic cardiovascular science has a pivotal role for the developing novel therapeutic approach. However, due to the inaccessibility of human heart tissue, we couldn’t obtain the sufficient amount of patient’s heart tissues. The discovery of human-induced pluripotent stem cells (iPSCs) is highly expected to provide the breakthrough to this obstruction. Through the patient-specific iPSCs-derived cardiomyocytes, we could analyze the patient-specific heart diseases directly and repetitively. Herein we introduce the outline of creation for cardiac disease modeling using patient-specific iPSCs. Within several topics, we present the actual representative methodologies throughout the process from the derivation of cardiomyocytes to those of functional analysis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676. doi:10.1016/j.cell.2006.07.024
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861–872. doi:10.1016/j.cell.2007.11.019
Egashira T, Yuasa S, Fukuda K (2013) Novel insights into disease modeling using induced pluripotent stem cells. Biol Pharm Bull 36(2):182–188
Lee G, Ramirez CN, Kim H, Zeltner N, Liu B, Radu C, Bhinder B, Kim YJ, Choi IY, Mukherjee-Clavin B, Djaballah H, Studer L (2012) Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat Biotechnol 30(12):1244–1248. doi:10.1038/nbt.2435
Choi SM, Kim Y, Shim JS, Park JT, Wang RH, Leach SD, Liu JO, Deng C, Ye Z, Jang YY (2013) Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 57(6):2458–2468. doi:10.1002/hep.26237
Charbord J, Poydenot P, Bonnefond C, Feyeux M, Casagrande F, Brinon B, Francelle L, Auregan G, Guillermier M, Cailleret M, Viegas P, Nicoleau C, Martinat C, Brouillet E, Cattaneo E, Peschanski M, Lechuga M, Perrier AL (2013) High throughput screening for inhibitors of REST in neural derivatives of human embryonic stem cells reveals a chemical compound that promotes expression of neuronal genes. Stem Cells 31(9):1816–1828. doi:10.1002/stem.1430
Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsuhashi T, Ohno Y, Tohyama S, Okata S, Seki T, Kuroda Y, Yae K, Hashimoto H, Tanaka T, Hattori F, Sato T, Miyoshi S, Takatsuki S, Murata M, Kurokawa J, Furukawa T, Makita N, Aiba T, Shimizu W, Horie M, Kamiya K, Kodama I, Ogawa S, Fukuda K (2012) Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res 95(4):419–429. doi:10.1093/cvr/cvs206
Mummery CL, Zhang J, Ng ES, Elliott DA, Elefanty AG, Kamp TJ (2012) Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111(3):344–358. doi:10.1161/circresaha.110.227512
Weng Z, Kong CW, Ren L, Karakikes I, Geng L, He J, Chow MZ, Mok CF, Keung W, Chow H, Leung AY, Hajjar RJ, Li RA, Chan CW (2014) A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. Stem Cells Dev 23(14):1704–1716. doi:10.1089/scd.2013.0509
Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T, Hashimoto H, Suzuki T, Yamashita H, Satoh Y, Egashira T, Seki T, Muraoka N, Yamakawa H, Ohgino Y, Tanaka T, Yoichi M, Yuasa S, Murata M, Suematsu M, Fukuda K (2013) Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12(1):127–137. doi:10.1016/j.stem.2012.09.013
Acknowledgment
This study was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology; Health and Labour Sciences Research Grant; the New Energy and Industrial Technology Development Organization, Japan; the Program for Promotion of Fundamental Studies in Health Science of the National Institute of Biomedical Innovation; Japan Science and Technology Agency; Research Center Network for Realization of Regenerative Medicine “The Program for Intractable Diseases Research utilizing Disease-specific iPS cells,” the Nakatomi Foundation; Japan Heart Foundation/Novartis Grant for Research Award on Molecular and Cellular Cardiology SENSHIN Medical Research Foundation; Kimura Memorial Heart Foundation Research Grant; Japan Intractable Diseases Research Foundation, Japan; the Cell Science Research Foundation; the Tokyo Biochemical Research Foundation; Suzuken Memorial Foundation; and the Japan Foundation for Applied Enzymology.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this protocol
Cite this protocol
Egashira, T. et al. (2014). Patient-Specific Induced Pluripotent Stem Cell Models: Characterization of iPS Cell-Derived Cardiomyocytes. In: Nagy, A., Turksen, K. (eds) Patient-Specific Induced Pluripotent Stem Cell Models. Methods in Molecular Biology, vol 1353. Humana Press, New York, NY. https://doi.org/10.1007/7651_2014_165
Download citation
DOI: https://doi.org/10.1007/7651_2014_165
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3033-3
Online ISBN: 978-1-4939-3034-0
eBook Packages: Springer Protocols